Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Mesenchymal drift may explain how aging cells lose their identity

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.

1 Jun 2026

Lactylation may drive pulmonary fibrosis through metabolic reprogramming pathways

Announcing a new article publication in BIO Integration. Pulmonary fibrosis (PF) is a progressive and irreversible interstitial lung disease that is characterized by destruction of alveolar architecture, excessive proliferation of fibroblasts, and aberrant deposition of extracellular matrix (ECM) but the precise pathogenesis has yet to be fully elucidated.

27 May 2026

Prenatal therapy for cystic fibrosis improves lifelong health outcomes

This Cystic Fibrosis Awareness Month, Children's Hospital Colorado (Children's Colorado) is highlighting a growing shift in care: starting cystic fibrosis treatment before birth to improve lifelong health outcomes and reduce hospital stays.

27 May 2026

New study tests vitamin D analog against pancreatic cancer

A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.

26 May 2026

Chronic liver disease threatens millions across Europe, report finds

Europe is facing a growing chronic liver disease threat, according to a new Series published today in The Lancet Regional Health – Europe, that engaged more than 75 co-authors from 30 countries and was led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by the "la Caixa" Foundation.

25 May 2026

Researchers uncover immune mechanisms behind polycystic kidney disease progression

A new review has illuminated a critical but often overlooked dimension of autosomal dominant polycystic kidney disease (ADPKD)—its immune microenvironment.

24 May 2026

Immunoproteasome plays emerging role in diabetes and metabolic complications

A newly published review article highlights the emerging importance of the immunoproteasome in the development and progression of diabetes and its wide-ranging complications, offering fresh perspectives on future therapeutic strategies.

24 May 2026

Early lung damage patterns uncovered in children with cystic fibrosis

Researchers have mapped how lung damage begins early in life for children with cystic fibrosis, providing new insights that will help reshape future care.

24 May 2026

Optimized extended PCLS culture system extends tissue viability up to two weeks

Precision-cut liver slice (PCLS) technology has long been regarded as a promising ex vivo platform because it preserves the native multicellular architecture of liver tissue.

22 May 2026

First-of-its-kind pregnancy hormone test reveals why female IBD patients face severe symptom flares

Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn's disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated.

21 May 2026

Biomimetic nanocomposite hydrogel promotes tendon healing and tissue regeneration

The new system, termed KGN@PB@CM, combines several advanced elements. Prussian blue (PB) nanozymes act as potent reactive oxygen species (ROS) scavengers, while kartogenin (KGN)-a small molecule that promotes stem cell migration and tenogenic differentiation-is loaded onto the PB core.

20 May 2026

Recent advancements in the development of models to study primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare non-communicable disorder that affects the liver. Chronic inflammation in and around the bile duct is followed by the development of fibrotic obstructions within the duct, causing bile to accumulate within the liver.

19 May 2026

Study measures smoking-related mechanical changes in human lungs

For the first time, scientists have directly measured how smoking changes the mechanical behavior of human lung tissue.

19 May 2026

Study identifies breakthrough drug combination for early-stage Peyronie’s

Combining two widely prescribed drug classes could provide the first effective treatment for early-stage Peyronie's disease, according to a new study published in The Journal of Sexual Medicine.

15 May 2026

Thyroid hormone profiles provide critical prognostic clues for patients facing liver failure

Early and accurate prognostic assessment is crucial to prevent disease progression in liver failure. Thyroid hormones (THs), particularly triiodothyronine (T3), are key metabolic regulators and play an important role in liver regeneration. Liver failure is frequently complicated by non‑thyroidal illness syndrome (NTIS), characterized by low T3 with normal or slightly elevated TSH and T4.

14 May 2026

New imaging technique maps 38000 liver cells to solve fibrosis

The liver is often called a "silent organ," as it can sustain significant damage without obvious symptoms. But when injury is prolonged, whether from alcohol, poor diet, or chronic hepatitis virus infection, it triggers fibrosis: a progressive hardening and scarring of liver tissue.

14 May 2026

Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection.

14 May 2026

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

From Society for Laboratory Automation and Screening (SLAS) 13 May 2026

Wearable wireless polygraph tracks hidden stress signals

Northwestern University engineers have developed a small, wireless polygraph system you can wear.

13 May 2026

Air pollution linked to rising kidney disease hospitalization risks

A study supported by FAPESP and published in the journal Scientific Reports showed a strong correlation between the concentration of particulate matter in the air of São Paulo, Brazil – primarily emitted by vehicle fuel combustion – and kidney disease.

13 May 2026